• Home
  • About
  • News
  • Events
  • Shop
  • Directory
  • Contact Us
Search
Sign in
Welcome! Log into your account
Forgot your password? Get help
Password recovery
Recover your password
A password will be e-mailed to you.
PsyNews.com
  • Home
  • About
  • News
  • Events
  • Shop
  • Directory
  • Contact Us
Home Featured Page 267

Featured

Latest
  • Latest
  • Featured posts
  • Most popular
  • 7 days popular
  • By review score
  • Random

Chad Charles – Integrating 5-MeO-DMT: Therapy, Harm Reduction, and Best Practices

Dispatch: The Neurobiology of Psychedelics Gordon Research Conference — Circuitry, Consciousness, and Clinical Horizons (Part 2)

William Leonard Pickard interviews Bryan Hubbard about the new policy frontier of Ibogaine

Pα+ Psychedelic Bulletin #204: FDA Keeps GH Research’s 5-MeO-DMT on Ice; Makary’s Priority Voucher Pilot Launches, Mentions Innovative PTSD Treatments; HALT Fentanyl Act Could...

June 2025 Psychedelic Patent Update

NeonMind Engages Certara to Advance its Synthetic Psilocybin Drug Candidates for...

DemeRx Receives MHRA Approval for DMX-1002 (Ibogaine) to Commence Phase 1/2a...

Nova Mentis Upgrades U.S. Listing to the OTCQB Venture Market

Group Ketamine-Assisted Psychotherapy: Practice and Promise of a New Frontier

Mydecine Innovations Group Announces Plans to Spin Out of its [U.S.]...

MindMed Increases Cash on Hand to CAD $205.2m (USD $162m), Closes...

The Pitfalls and Challenges of Psychedelic Medicine

Cybin Announces API Synthesis and Optimization of Multiple Tryptamine Derivatives and...

Optimi Health Accelerates Psilocybin Clinical Trial Program with IMPACT

Red Light Holland’s Psychedelic Virtual Reality Experience, Wisdom, Narrated by Global...

1...266267268...293Page 267 of 293

EDITOR PICKS

Chad Charles – Integrating 5-MeO-DMT: Therapy, Harm Reduction, and Best Practices

Dispatch: The Neurobiology of Psychedelics Gordon Research Conference — Circuitry, Consciousness,...

William Leonard Pickard interviews Bryan Hubbard about the new policy frontier...

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY

    ABOUT US
    PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.
    FOLLOW US
    ©